Health Professionals
Ongoing medical support and testing
Dr Kaj Winter, MD, DMSci, from the department of Clinical Biochemistry, Fredricksberg Hospital, University of Copenhagen, Denmark, has been involved in researching and testing Rose-Hip for over a decade.
Trial #1
PATIENTS: 100 patients, all with X-ray verified diagnosis of osteoarthritis of the hip or knee and all awaiting surgery. Fifty of the patients were given 5 Rose-Hip Vital capsules twice daily and the other 50 were given identical placebos. Both groups were treated for 4 months.
AIM: To test the impact of Rose-Hip Vital on pain, stiffness and certain daily functions of people suffering severe osteoarthritis. The study was double-blind, randomized and placebo controlled.
CONCLUSION: The present data indicates Rose-Hip Vital reduces osteoarthritic pain in the hip and knee joints. Stiffness of the hip also significantly declined. Patients reported less pain during daily activities and improvement of energy, motivation for daily activity, and sleeping patterns improved.
TEST CONDUCTED BY: Warholm O, Skaar S, Hedman E, Molmer H.M, Eik L. At the Department of Orthopedic Surgery, Vestfold Central Hospital, Norway.
Trial #2
PATIENTS: 42 middle-aged women with non-rheumatic joint pain. Half the patients were given 5 Rose-Hip Vital capsules twice daily, the other half identical placebos over a three month period. Then the original group taking Rose-Hip Vital were changed to placebo and vice versa for another three months. Investigation was performed at the beginning and at the end of each of the two treatment periods. This was a randomised, double-blind cross-over test.
AIM: To investigate whether Rose-Hip Vital can reduce pain and stiffness in middle-aged women suffering from non-rheumatic joint pain. To test if a reduction in pain, if present, would affect the patient’s daily activities. To investigate if patients evaluation of the severity of their disease was changed by treatment.
CONCLUSION: While on Rose-Hip Vital pain and stiffness significantly declined by approximately 50%. When the 21 patients who were given Rose-Hip Vital before the placebo were evaluated separately, the results were even more in favour of Rose-Hip Vital. This suggests a carry-over affect. Patients Global Assessment of Disease Severity (PGADS) also significantly declined and thus an improvement in various daily activities resulted.
TEST CONDUCTED BY: Rein E, Kharazmi A, Winther K. At the Department of Clinical Research, Kolding; Department of Clinical Microbiology, Rigs Hospital; Department of Clinical Biochemistry, Copenhagen County Hospital; and University of Copenhagen, Denmark.
Trial #3
PATIENTS: 30 patients with osteoarthritis of at least one hand were randomly allocated treatment with either 5 Rose-Hip Vital capsules twice daily or identical placebos. This was a double-blind crossover where after 3 months the groups switched, totaling 6 months.
AIM: To test the impact of Rose-Hip Vital on pain, stiffness and overall feeling of discomfort on those suffering osteoarthritis of the hands. Before and after each of the two treatment periods the patients gave their evaluation of pain and stiffness during 15 daily activities (see below) on a scale of 0 to 10 (10 being worst possible).
CONCLUSION: The present data suggests Rose-Hip Vital significantly reduces pain & stiffness in patients with osteoarthritis of the hand(s). Overall discomfort also dropped.
TEST CONDUCTED BY: Rein E, Kharazmi A, Winther K. At the Department of Clinical Research, Kolding; Department of Clinical Microbiology, Rigs Hospital; Department of Clinical Biochemistry, Copenhagen County Hospital; and University of Copenhagen, Denmark.
